KLH-conjugated synthetic peptide encompassing a sequence within human PMEL. The exact sequence is proprietary.
Conjugation:
Unconjugated
Alternative Names:
D12S53E, PMEL17, SILV, Melanocyte protein PMEL, ME20-M, ME20M, Melanocyte protein Pmel 17, Melanocytes lineage-specific antigen GP100, Melanoma-associated ME20 antigen, P1, P100, Premelanosome protein, Silver locus protein homolog
PMEL/Melanoma gp100 is a type 1 transmembrane glycoprotein primarily expressed in pigment cells of the skin and eye, and overexpressed in more than 75% of human melanomas . It is involved in the transformation of melanosomes from stage I to stage II, forming the fibrillar matrix necessary for pigmentation of the cell . The synthesis and modification of PMEL/Melanoma gp100 is done in the endoplasmic reticulum (ER) and transferred to the Golgi complex where it is cleaved into two disulfide-linked subunits, Malpha and Mbeta. The cleavage of the large luminal Malpha fragment is required for the formation of the fibrils that are the structure for melanin synthesis . The ability for PMEL/Melanoma gp100 to form functional amyloids makes it an interesting protein to study when looking at pathological amyloids in neurodegenerative diseases, such as Alzheimers disease and Parkinsons disease . Due to melanocyte-restricted expression of this protein, PMEL/Melanoma gp100 is considered a tumor-associated antigen that can be targeted by immunotherapeutic approaches to treat melanoma .
The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Form:
Mouse IgG2b. Liquid in PBS containing 50% glycerol, 0.2% BSA and 0.01% sodium azide.
Application Dilute:
IHC (1/100 - 1/300)
Application Notes:
Recognizes endogenous levels of PMEL protein.
* VAT and and shipping costs not included. Errors and price changes excepted
